Garrison Point Advisors LLC cut its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,408 shares of the company’s stock after selling 80 shares during the period. Johnson & Johnson makes up approximately 2.4% of Garrison Point Advisors LLC’s holdings, making the stock its 4th largest holding. Garrison Point Advisors LLC’s holdings in Johnson & Johnson were worth $2,898,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Lincoln Capital Corp increased its stake in shares of Johnson & Johnson by 15.9% during the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after purchasing an additional 183 shares in the last quarter. Ieq Capital LLC increased its stake in shares of Johnson & Johnson by 5.1% during the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after purchasing an additional 6,154 shares in the last quarter. RFG Advisory LLC increased its stake in shares of Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after purchasing an additional 594 shares in the last quarter. Willis Investment Counsel increased its stake in shares of Johnson & Johnson by 0.4% during the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after purchasing an additional 1,358 shares in the last quarter. Finally, Wambolt & Associates LLC increased its stake in shares of Johnson & Johnson by 2.5% during the 4th quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock worth $2,566,000 after purchasing an additional 355 shares in the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
JNJ has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Atlantic Securities lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday, April 19th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. Piper Sandler lowered their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Finally, Raymond James lowered their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.
Johnson & Johnson Stock Up 0.9 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The company’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.67 EPS. Analysts forecast that Johnson & Johnson will post 10.67 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a $1.19 dividend. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 annualized dividend and a dividend yield of 2.88%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.
Insider Activity
In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- United Parcel Service Delivers A Warning To The Market
- Pulte Homes Is Hosting The Better, More Profitable Open House
- Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
- A Top Is In For McDonald’s Corporation Stock
- Strong Demand Makes Cleveland-Cliffs an Undervalued Mid-Cap
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
